Increased Survival Rates and Decreased Disease Progression Rates Are the
Advantages, According to a New Report from Decision Resources
WALTHAM, Mass., Aug. 7 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Wyeth's Torisel and Roche/Genentech's Avastin will challenge Pfizer's Sutent as the clinical gold standard for the treatment of metastatic renal cell carcinoma. According to the new report entitled Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study, both Torisel and Avastin offer increased overall survival rates as well as decreased disease progression times.
"Metastatic renal cell carcinoma is an end-stage disease in which the primary goal of treatment is to prolong survival," said Mohamed Muhsin, analyst at Decision Resources. "Phase III clinical trials have shown Torisel to increase the median overall survival rates of patients by 49 percent. High rates of partial response and stable disease, extended median time to progression, and overall survival rates for patients on Torisel are promising. Phase II trials for Avastin have shown that 61% of patients had stable disease. The median progression-free survival rate was eleven months, and the one-year progression-free survival rates for patients with objective response, minor response, and stable disease were 80%, 57% and 27%, respectively."
About Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study
Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study covers the current and future state of the metastatic renal cell carcinoma drug market. The report includes the following:
-- More than 3,000 physician responses that define drug attributes that
drive prescription now and in the future.
* Clinical end point tradeoffs that are most influential to
* Areas o
|SOURCE Decision Resources, Inc.|
Copyright©2007 PR Newswire.